1526Survival of hospitalized COVID-19 patients with multimorbidity in Hidalgo Mexico

• Published in: International journal of epidemiology Vol. 50; no. Supplement_1
• Main Authors: Bustos-Vazquez, Eduardo, Padilla-González, Eduardo
• Format: Journal Article
• Language: English
• Published: 01.09.2021
• ISSN: 0300-5771; 1464-3685
• DOI: 10.1093/ije/dyab168.104

Abstract Background The growing number of patients with complex clinical profiles has contributed to the increasingly deaths. The aim is to estimate survival and risk factors associated with hospitalized COVID-19 patients with multimorbidity in the state of Hidalgo, Mexico during 2020 to April 2021. Material and Methods An observational, longitudinal, prospective and analytical study was carried out in 11,955 hospitalized COVID-19 patients with multimorbidity from the Epidemiological Surveillance System for Respiratory Disease of Hidalgo. The variables of interest were survival of hospital stay per day and multimorbidity adjusted for age, sex, occupation, days of demand for care, and days of mechanical ventilation use. Kapplan-Meiner estimators, Log-Rank tests and Cox proportional hazard method were using. Results Hospitalized COVID-19 patients with multimorbidity survival was 53.5%. The probability of survival is reduced to 50% from day 17 of hospital stay. The shortest survival rate corresponds to cases with Hypertension + Chronic Kidney Disease (RR: 9.46, 95% CI 2.63-37.92), Diabetes + Hypertension + Chronic Kidney Disease (RR: 1.83, 95% CI 1.52-2.20), Diabetes + Hypertension + Obesity (RR: 1.35, 95% CI 1.16-1.57) and Diabetes + Hypertension (RR: 1.31, 95% CI 1.19-1.45). The use of mechanical ventilation for more than 14 days increases the survival rate (RR: 0.53, 95% CI 0.49-0.57). The survival rate from occupation increase in employees, students and health workers compared to the unemployed. Conclusions Multimorbidity increases the effect of the clinical and epidemiological interrelationships of the coexistence of multiple diseases in the same individual and reduces the survival of COVID-19 in hospitalized patients.